Skip to Main Content

Paper Details

Adjusted comparison of outcomes between patients from CARTITUDE-1 multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world cl
6
2023
Ciltacabtagene, Patients, anti-CD38 antibody, carfilzomib, chimeric, chimeric antigen receptor, cilta, cilta-cel, cyclophosphamide, dexamethasone, multiple myeloma, myeloma, patients, pomalidomide, pomalidomidedexamethasone
Author NameAffiliation
Andrzej JakubowiakUniversity of Chicago.
Alexander Keith StewartUniversity Health Network and the Princess Margaret Cancer Centre
Sundar JagannathMount Sinai Medical Center.
  • 1 - 3

Datasets

Release 1.2